Adcytherix

About Adcytherix

Adcytherix is a biopharmaceutical company dedicated to developing novel antibody drug conjugates (ADCs) to address high unmet need diseases, particularly cancer. The company is led by an experienced management team and supported by world-leading experts in ADC development, with headquarters in Marseille, France.

Products & Services

Antibody Drug Conjugates (ADCs):Novel therapies designed to treat diseases with high unmet needs, such as cancer.

Specialties

Antibody Drug Conjugates (ADC) Development Cancer Treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 122000000 MR: - FA: €105 million FAN: 122000000	D: 2025-10-16 FD: 2025-10-16	10 investors
2	RT: Seed T: - FT: Seed	A: 32400000 MR: - FA: € 30m FAN: 32400000	D: 2024-06-11 FD: 2024-06-11	5 investors

Series A Latest

2025-10-16

$122.0M

10 investors (Pro only)

Seed 2024-06-11

$32.4M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jack Elands

Founder, Chief Executive Officer

C

Carsten Dehning

Co-founder, Chief Financial Officer

X

Xavier Preville

Co-founder, VP and head of research & preclinical development

T

Thierry Menguy

VP and head of CMC operations

I

Inka Pawlitzky

VP and head of clinical development

J

Julia Gavrilyuk

VP and head of ADC technology development

View 9 more team members with Pro

Unlock Full Team Directory

Recent News

Adcytherix Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised